anastrozole / Generic mfg. - LARVOL DELTA

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Washington | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Mar 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Choline transporter CTL2/SLC44A2 as a therapeutic target for breast cancer (SG-BCC 2025) - "The breast cancer drugs tamoxifen, toremifene, and anastrozole significantly inhibited choline uptake in MCF-7 cells. These data suggest that CTL2/SLC44A2-mediated choline uptake mechanism exists specifically in breast cancer cells. CTL2/SLC44A2-mediated choline transport system provides a target molecule for breast cancer therapy. Future development of therapeutic agents for breast cancer targeting CTL2/SLC44A2 is expected."

Breast Cancer • Oncology • Solid Tumor • BRCA • CASP3 • CASP7

OATP1B-type transport function is a determinant of aromatase inhibitor-associated arthralgia susceptibility. (PubMed, Cancer Res Commun) - "Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Pain • Oncology • Solid Tumor

The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma. (PubMed, J Steroid Biochem Mol Biol) - "With higher efficacy than tamoxifen, AIs such as anastrozole, letrozole, and exemestane have become widely employed in adjuvant and first-line treatments for advanced breast cancer. To provide a comprehensive overview of AIs in the treatment of ER+ breast cancer, this study examined the pharmacokinetics, clinical uses, mechanisms of action, and problems with treatment resistance. To maximize therapeutic approaches and enhance patient outcomes in the treatment of ER breast cancer, it is imperative to understand these characteristics."

Journal • Review • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER

CHEMOTHERAPY (TRASTUZUMAB)-INDUCED PNEUMONITIS: A CASE REPORT (SCCM 2025) - "She had been on trastuzumab and anastrozole for four years...She was started on intravenous methylprednisolone and discharged on oral prednisone and 2 L of oxygen via nasal cannula due to persistent hypoxia...Corticosteroids are the mainstay of treatment for drug-induced pneumonitis. Oxygen therapy, bronchodilators, and supportive measures may be required depending on the severity of the respiratory symptoms."

Case report • Clinical • Breast Cancer • Cardiovascular • Congestive Heart Failure • Cough • Heart Failure • HER2 Breast Cancer • HER2 Positive Breast Cancer • Inflammation • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • HER-2

EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (clinicaltrials.gov) - P3 | N=8000 | Recruiting | Sponsor: Eli Lilly and Company | N=6000 ➔ 8000

Enrollment change • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity. (PubMed, Biomedicines) - "A supraphysiological dose of testosterone may impair endometrial receptivity through dysregulation of the LIF signalling pathway, potentially affecting fertility."

Journal • Preclinical • Hematological Malignancies • Leukemia • Oncology • JAK1 • LIFR • MUC1 • STAT3

Secondary Breast Angiosarcoma Five Years After Radiation Therapy for Ductal Carcinoma In Situ. (PubMed, Cureus) - "We present the case of a 56-year-old woman with a history of high-grade ductal carcinoma in situ (DCIS) of the breast, previously treated with lumpectomy, sentinel lymph node biopsy, radiation therapy, and anastrozole...Educating patients about potential late complications of radiation therapy and advising against additional risk factors, such as ultraviolet 2 exposure from tanning beds, are important. Further research is needed to establish evidence-based guidelines for the diagnosis, treatment, and follow-up of RIAS."

Journal • Angiosarcoma • Breast Cancer • Oncology • Sarcoma • Solid Tumor

Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "Postoperative radiotherapy significantly reduces local and regional recurrence following BCS in early estrogen receptor-positive elderly BC with limited value on distant recurrence or mortality. The risk-benefit ratio should be determined for every patient to avoid overtreatment of a significant proportion of patients."

Clinical • Journal • Retrospective data • Review • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER

Severe Biventricular Failure, ARDS, and DIC Linked to Fadogia Agrestis, Trimethylglycine, and Anastrozole: A Case Report on Unregulated Supplement and AAS Use (ATS 2025) - No abstract available

Case report • Clinical

Remote Monitoring Of Physical Activity In Randomized Clinical Trial Of Anastrozole In PAH - The PHANTOM Study (ATS 2025) - No abstract available

Clinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Case of a Patient with Hormone-Positive HER2-Negative Breast Cancer Whose Multiple Brain Metastases Disappeared after Abemaciclib Combination Therapy (PubMed, Gan To Kagaku Ryoho) - "Under the diagnosis of left breast cancer with cT2N3cM1(OSS), Stage Ⅳ, Luminal B like, we started treatment with anastrozole, leuprorelin, abemaciclib and denosumab. It also has a longer intracerebral retention time than other CDK4/6 inhibitors. Combination therapy with abemaciclib may be a useful treatment option for HR-positive, HER2-negative breast cancer with brain metastases."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Pain • Solid Tumor • HER-2

HIRA to remove…drugs from Group 2 anticancer list, update reimbursement criteria (Korea Biomedical Review) - "The move, which is aimed at overhauling the reimbursement system and reflecting the latest clinical evidence, will take effect on March 1. The drugs that will be deleted from the list of Group 2 anticancer drugs are albumin-bound paclitaxel, aldesleukin(IL- 2), anagrelide, anastrozole, belotecan, capecitabine..."

Reimbursement • Oncology

Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ruth O'Regan | N=48 ➔ 30

Enrollment change • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Case of Locally Advanced Breast Cancer Reconstructed with Rhomboid Flap after Mastectomy (PubMed, Gan To Kagaku Ryoho) - "Mastectomy with about 10×10 cm skin resection plus sentinel lymph node biopsy was performed in August 2022 after neoadjuvant endocrine therapy(anastrozole)...The rhomboid flap was designed quickly and easily with no special instruments, and resulted in a good cosmetic outcome. Therefore, rhomboid flap reconstruction was a very useful method to cover the skin defect after mastectomy of locally advanced breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor

Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study. (PubMed, Clin Pharmacol Ther) - "Of the 10 drug pairs evaluated, hydrochlorothiazide vs. dihydropyridine CCBs showed meaningful reductions in 3 out of 4 analyses that addressed specific biases including informative censoring, reverse causality, and outcome misclassification (pooled hazard ratios [95% confidence intervals] across Medicare and CPRD: 0.81 [0.75-0.88] in Analysis 1, 0.98 [0.92-1.06] in Analysis 2, 0.83 [0.75-0.91] in Analysis 3, 0.75 [0.65-0.85] in Analysis 4). Amiloride vs. triamterene, although less precise, also suggested a potential reduction in risk in 3 out of 4 analyses (0.86 [0.66-1.11] in Analysis 1, 0.98 [0.79-1.23] in Analysis 2, 0.74 [0.54-1.00] in Analysis 3, 0.61 [0.36-1.05] in Analysis 4). Other analyses suggested likely no major differences in risk (probenecid, salbutamol, montelukast, propranolol/carvedilol, and anastrozole) or had limited precision precluding a definitive conclusion (semaglutide, ciloztozol, levetiracetam). Future replication studies should be considered..."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

A Rare Case of Benign Phyllodes Tumor of the Breast Responding to Anastrozole. (PubMed, Cureus) - "There is no evidence of phyllodes tumors expressing endocrine receptors, nor is there an established role for endocrine therapy in treating these tumors. We present a case of a large phyllodes tumor that showed a clinical response to treatment with anastrozole."

Journal • Breast Cancer • Oncology • Solid Tumor

Breast Carcinoma Metastasis In Endometrium - A Case Report (ESGO 2025) - "She continued treatment with Anastrozole and Trastuzumab. For suspected uterine metastasis, biopsy with histopatologyc and immunohistochemical analysis are necessary to verify tumor origin, guiding treatment. Conclusion Given the rarity of uterine metastasis from breast cancer, further studies are warranted to improve diagnostic and therapeutic strategies."

Case report • Clinical • Breast Cancer • Endometrial Cancer • Gynecologic Cancers • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • HER-2

Efficacy Of Preoperative Hormone Therapy In Operable Hormone Receptor-Positive Breast Cancer: A Prospective Study From The Salah Azaiz Institute (ESGO 2025) - "Clinical and ultrasound responses to POHT, administered as tamoxifen or anastrozole, were assessed over a mean duration of approximately six weeks. Conclusion The study found that clinical and ultrasound response rates to POHT were lower than those reported in existing literature, suggesting that extending the duration of hormone therapy may improve outcomes. Further randomized trials with larger cohorts are necessary to better understand the role of POHT in managing operable HR+ breast cancer and to establish optimal treatment durations for enhanced patient prognosis."

Clinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Metastatic Breast Cancer To Ovaries And Endometrium: A Rare Case (ESGO 2025) - "Patient started palliative chemotherapy with anthracycline and cyclophosphamide, however presented vaginal bleeding...Patient is alive and undergoing adjuvant immunotherapy with anastrozole along with zoledronic acid. Conclusion Breast cancer metastasis to the gynecologic tract is rare, especially when identified in both ovaries and endometrium simultaneously. Attention to clinical symptoms such as vaginal bleeding is important to identify primary carcinoma or metastatic disease as it changes the course of treatment."

Clinical • Metastases • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • ER

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. (PubMed, ESMO Open) - P3 | "In patients with hormone receptor-positive breast cancer, the luminal B-like subtype was associated with a significantly worse prognosis when compared with the luminal A-like subtype. Extended anastrozole therapy halved the risk of DR and BCSM in patients with luminal A-like tumours, whereas no effect was seen in patients with luminal B-like tumours."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial. (PubMed, J Clin Oncol) - No abstract available

Journal • P3 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase). (PubMed, Pharmacol Res Perspect) - "The reporting odds ratio (ROR) and its 95% CI for reporting dementia are exemestane, 2.08 (1.35-3.19); anastrozole, 1.59 (1.09-2.32); and letrozole, 1.43 (1.05-1.95) and for Alzheimer's disease are exemestane, 0.94 (0.30-2.92); anastrozole: 2.63 (1.55-4.45); and letrozole, 1.33 (0.76-2.35). Signals of disproportionate reporting have been observed between the occurrence of dementia, dementia Alzheimer's type, and senile dementia with aromatase inhibitors, which is in line with estrogen functions and aromatase activity, as well as the findings from preclinical studies. Additional research is required to elucidate this intricate matter."

Adverse events • Journal • Alzheimer's Disease • Breast Cancer • CNS Disorders • Cognitive Disorders • Dementia • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: Hongmei Zheng, PhD

New trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor

ST-Elevation Myocardial Infarction (STEMI) Due to Left Ventricular Thrombus Embolization: Implications of Multiagent Hormone Replacement Therapy. (PubMed, Cureus) - "We present the case of a 41-year-old physically active male patient on long-term combination hormone replacement therapy (HRT) (testosterone, tamoxifen, and anastrozole) who developed ST-elevation myocardial infarction (STEMI) complicated by peri-infarction pericarditis (PIP)...He was discharged on warfarin and continues regular follow-up at the anticoagulation clinic. His first follow-up visit to cardiology is yet to occur. This case highlights the potential cardiovascular risks associated with combined HRT, underscoring the need for clinicians and patients to be aware of its possible role in provoking thrombotic events and myocardial infarction in younger individuals."

Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis